16th Jul 2009 12:05
Synergy Healthcare Director/PDMR Shareholding
16 July 2009
SYNERGY HEALTH PLC ("the Company")
The Company has been notified that the following award of LTIP options has been made, pursuant to the Company's LTIP scheme, to certain Directors/Persons Discharging Managerial Responsibility ("PDMR") over 322,050 ordinary shares of 0.625 pence each in the Company ("Ordinary Shares"), as follows:
|
Name |
No. of LTIP options |
Market price per share (£) |
Value (£) |
|
Richard Steeves |
114,841 |
5.045 |
579,372.85 |
|
Ivan Jacques |
59,972 |
5.045 |
302,558.74 |
|
Marcello Smit |
50,339 |
5.045 |
253,960.26 |
|
Paul Santing |
36,486 |
5.045 |
184,071.87 |
|
Paul Wynne |
13,832 |
5.045 |
69,782.44 |
|
Adrian Coward |
25,768 |
5.045 |
129,999.56 |
|
Alison Speak |
20,812 |
5.045 |
104,996.54 |
In accordance with the LTIP scheme rules for conditional awards, the LTIP options were made based on a share price of 504.50 pence per Ordinary Share, being the average quoted market price of the Company's shares on the three dealing days prior to the date of grant.
The LTIP options have been granted on a conditional basis and no shareholder rights will be conferred upon the grantee until the LTIP options have vested. Such vesting is subject to the achievement of the performance criteria of the scheme over the three year measurement period to 16 July 2012.
Furthermore, the Company has been notified that the following award of share options have been allocated, pursuant to the Company's Executive Share Option Plan, to certain PDMRs, over 25,816 Ordinary shares of 0.625 pence each in the Company, as follows:
|
Name |
No. of LTIP options |
Market price per share (£) |
Value (£) |
|
Richard Palmowski |
6,635 |
5.045 |
33,473.58 |
|
Alison Payne |
6,937 |
5.045 |
34,997.17 |
|
George Dijkstra |
12,244 |
5.045 |
61,770.98 |
In accordance with the Company's Executive Share Option Plan, options are exercisable at a price equal to the average quoted market price of the Company's shares on the three dealing days prior to the date of grant. Exercise of the options is subject to performance conditions determined by the Remuneration Committee and are linked to a sustained and significant improvement in the underlying financial performance of the Company over a three year vesting period.
Enquiries
Ivan Jacques (Group Finance Director and Company Secretary)
+44 (0) 1793 891 861
Related Shares:
SYR.L